Drug Profile
MBX 2982
Alternative Names: MBX-2982; SAR-260093Latest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator Metabolex
- Developer AdventHealth Translational Research Institute; CymaBay Therapeutics
- Class Antihyperglycaemics; Benzene derivatives; Ethers; Hepatoprotectants; Piperidines; Pyrimidines; Small molecules; Tetrazoles; Thiazoles
- Mechanism of Action GPR119 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Liver disorders; Type 1 diabetes mellitus; Type 2 diabetes mellitus